Health Disparities in Black Patients Living With Epilepsy: Findings From a **Survey of US Neurologists**

Background

- The epilepsy experience differs between individuals and is influenced by many factors, including inequities based on socially defined race and ethnicity.¹⁻³
- A history of racism places certain groups at a disadvantage.⁴ • Previous studies have suggested a disparity in access to healthcare and health outcomes
- for Black patients living with neurologic disorders, including epilepsy, compared with their White counterparts.^{1,5}

Objective

• To better understand factors contributing to health disparities in Black patients living with epilepsy (PLWE) and the value of programs for healthcare professionals (HCPs) to reduce disparities.

Methods

STUDY DESIGN

- Online, cross-sectional market research survey was administered to neurologists (November 8, 2022, to November 18, 2022) using InCrowd's MicroSurvey platform.
- Screening questions assessed eligibility; criteria included having $\geq 20\%$ of Black PLWE among all their PLWE, management of \geq 10 PLWE in the last 30 days, and working in academic or community settings.
- Survey guestions assessed understanding and recognition of health disparities in PLWE and the value of programs for HCPs.

ANALYSES

• T-tests with Bessel's correction (significant differences at a 95% confidence level) were carried out for the following subgroups: by setting (academic neurologists vs community neurologists) and by subspecialty (neurologists with an epilepsy subspecialty vs neurologists with a different subspecialty vs general neurologists with no subspecialty).

Results


NEUROLOGISTS AND PATIENTS

- Neurologists' subspecialties were epilepsy (n=50 [49.5%]), a different subspecialty (n=30 [29.7%]), and no subspecialty (general neurology) (n=21 [20.8%]).
- Different practice settings included academic/teaching hospitals (n=49 [48.5%]) and community settings: community-based multispecialty group private practice (n=19 [18.8%]), community-based single specialty group private practice (n=18 [17.8%]), community-based solo private practice (n=9 [8.9%]), and community non-teaching hospital (n=6 [5.9%]).


Demographic characteristics of neurologists and their patients

	ACADEMIC (n=49)	COMMUNITY (n=52)	ALL RESPONDENTS (N=101)		
Race/ethnicity of neurologists, n (%) ^a					
White	20 (40.8)	20 (38.5)	40 (39.6)		
Asian	10 (20.4)	15 (28.8)	25 (24.8)		
Hispanic	2 (4.1)	2 (3.8)	4 (4.0)		
Black	1 (2.0)	1 (1.9)	2 (2.0)		
Other	3 (6.1)	2 (3.8)	5 (5.0)		
Prefer not to answer	13 (26.5)	12 (23.1)	25 (24.8)		
Types of patients managed monthly, mean, n ^b					
Epilepsy	96.4	63.9	79.7		
Migraine	69.5	80.9	75.4		
Neuropathy/pain	36.1	56.5	46.6		
Race/ethnicity of patients with epilepsy seen by neurologists, mean, % ^c					
White	43.8	49.4	46.7		
Black	28.9	27.7	28.3		
Hispanic	16.2	14.1	15.1		
Asian	8.3	6.3	7.3		
Other	2.7	2.4	2.6		

³Survey question: Which of the following best describes your ethnicity?; ^bScreening question: In a typical 30-day period, how many of the following patients do you personally manage/treat? Note: This question is asking for the total number of patients (not patient visits) managed by you, personally, not those managed by your entire practice/network; cS5: To better understand the make-up of your patient population, what percentage of your epilepsy patient population are of the following ethnicities? Note: Your total must sum to 100%. Choices (random order): 1. _% White, 2. _% Black [SCREEN OUT IF <20%], 3. _% Asian, 4. _% Hispanic, 5. _% Other. HCP, healthcare professional.




AWARENESS OF HEALTH DISPARITIES



*Statistically significant difference (p<0.05) in the percentage of neurologists in academic vs community settings who agree with the statement.

health outcomes^a




Please think about the Black epilepsy patients that you are currently managing. To what extent, if any, do the following situations have [an impact] on health outcomes for your epilepsy patients? Questions were answered on a 5-point scale, where: 1 = Insignificant/no impact, 2 = Minor negative impact, 3 = Moderate negative impact, 4 = Major negative impact, 5 = Highly significant/severe negative impact. ED, emergency department; OOP, out-of-pocket; PLWE, patients living with epilepsy.


^aSurvey question: Please rate your agreement with the statement below: 'Racism is a social determinant of health.' Questions were answered on a 5-point scale, where: 1 = Completely disagree, 2 = Somewhat disagree, 3 = Neither agree nor disagree, 4 = Somewhat agree, 5 = Completely agree.

Situations considered by neurologists to have a 'major' or 'highly significant/severe' negative impact on patient

In all PLWE



In Black PLWE



ED: emergency department; OOP, out-of-pocket; PLWE, patients living with epilepsy.

Situations considered by neurologists to have a 'major' or 'highly significant/severe' negative impact on patient health outcomes, by practice setting^a

2 = Minor negative impact, 3 = Moderate negative impact, 4 = Major negative impact, 5 = Highly significant/severe negative impact. Statistically significant difference (p<0.05) in the percentage of neurologists in academic vs community settings reporting situations that have a 'major' or 'highly significant/severe' negative impact on health outcomes.

• Neurologists with an epilepsy subspecialty (n=50) and those with a different subspecialty (n=30) were more likely than general neurologists (n=21) to report 'do not have access to reliable transport' as a situation that has a major/severe impact (78.0% and 66.7% vs 33.3%; p<0.05). • Neurologists with an epilepsy subspecialty were more likely than neurologists with a different subspecialty to report 'treatment refusal' as a situation having a major/severe impact (74.0% vs 46.7%; p<0.05).


NEUROLOG

Speaker seri disproportio **Cultural sen** Speaker ser navigating a therapies for

Programs th Black/minor **Contribute t**

specialists of PLWE, patients living with epilepsy

Likelihood of participating in HCP-focused programs^a



Survey question: How likely would you be to participate in any of the following? Questions were answered on a 5-point scale, where: 1 = Very unlikely, 2 = Somewhat unlikely Neither likely nor unlikely, 4 = Somewhat likely, 5 = Very likely, HCP, healthcare provide

Limitations

- Risk of response bias.

References

- 3. Saadi A, et al. Neurology 2017;88:2268-2275

UCB Pharma-sponsored. UCB Pharma was involved in the design of the study, the collection, analysis, and interpretation of data, and review of the poster. The authors thank the participants who contributed to this study. The authors acknowledge Bobby Jacob, PharmD (UCB Pharma, Smyrna, GA, USA) for managing the development of the poster, and Amy Lee, BS (Evidence Scientific Solutions, Philadelphia, PA, USA) for writing assistance, which was funded by UCB Pharma. Author contributions: All authors contributed to study design and data analysis and interpretation. All authors critically reviewed the poster and approved the final version for presentation. Author disclosures: I Ebong is an employee of University of Kentucky College of Medicine, Department of Neurology, the market research company commissioned to conduct the research with funding from UCB Pharma. P Eads and G Charles are employees of UCB Pharma.



mail: UCBCares@ucb.com American Epilepsy Society 77th Annual Meeting Orlando, FL, USA | December 1–5, 2023


1. Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA 2. UCB Pharma, Smyrna, GA, USA

PERCEPTIONS REGARDING HCP-FOCUSED PROGRAMS

HCP-focused programs considered by neurologists to be 'somewhat' or 'very important' for improving health outcomes for Black PLWE^a

ISTS, n (%)	ACADEMIC (n=49)	COMMUNITY (n=52)	ALL RESPONDENTS (N=101)
ies/learning series covering the issues onately impacting Black PLWE	36 (73.5)*	26 (50.0)	62 (61.4)
sitivity courses/learning series	36 (73.5)*	24 (46.2)	60 (59.4)
ies/learning series providing guidance on authorization access issues with epilepsy or uninsured/underinsured patients	34 (69.4)*	26 (50.0)	60 (59.4)
nat match Black/minority patients with rity HCPs	30 (61.2)	25 (48.1)	55 (54.5)
to scholarship programs for neurology of color	24 (49.0)	22 (42.3)	46 (45.5)

Survey question: How important are the following ideas for HCP-focused programs for continuing to improve treatment outcomes for Black patients living with epilepsy? Questions were answered on a 5-point scale, where: 1 = Very unimportant, 2 = Somewhat unimportant, 3 = Neither important nor unimportant, 4 = Somewhat important, 5 = Very important. Statistically significant difference (p<0.05) in the percentage of neurologists in academic vs community settings rating the importance of HCP-focused programs. HCP, healthcare provider



• Used database platform that included only neurologists with at least 20% of their epilepsy patient population consisting of Black patients, which may not be representative of the entire neurologist population treating Black PLWE.

• Answers to survey questions were self-reported and not verified through medical chart review.

Conclusions

 Neurologists perceived little differences in situations that have a negative impact on health outcomes between all PLWE and Black PLWE, except more physicians reported mistrust in the healthcare system for the latter group.

• More often, academic vs community neurologists report socioeconomic situations as having a negative impact on patient health outcomes.

• Increasing neurologist awareness of situations that have negative health outcomes in Black PLWE may help to address racial health disparities in this patient population. Speaker- and learning series focused on issues related to Black PLWE and navigating authorization access for epilepsy therapies were most often identified as HCP-focused programs that could improve health outcomes for Black PLWE.

1. Bensken WP, et al. Neurol Clin Pract 2023;13(1):e200101.

2. Fantaneanu TA, et al. Seizure 2016;40:52-56.

4. Churchwell K, et al. *Circulation* 2020;142(24):e454-e468.

5. Saadi A, et al. Neurology 2017;88(24):2268-2275.

For a copy of this poster, use your smartphone to scan the QR code, download from the website pelow, visit the UCB medical affairs booth at the exhibit, or contact UCB**Cares**®

Vebsite: UCBposters.com/AES2023; Poster ID: 1.378

hone: +1-844-599-CARE (2273)

